FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2035994482> ?p ?o ?g. }

• W2035994482 endingPage "338" @default.
• W2035994482 startingPage "338" @default.
• W2035994482 abstract "Docetaxel is the first line chemotherapy currently used to treat patients with symptomatic metastatic castration resistant prostate cancer. Although it provides survival benefits, it is associated with significant side effects. Novel therapeutic options are needed for patients with metastatic castration resistant prostate cancer and an approach is combining docetaxel with chemosensitizing agents. Metformin has been shown to improve the survival of patients with breast, lung and endometrial cancer receiving chemotherapy, and enhance chemotherapeutic efficacy in breast cancer and colon cancer cells. However, to our knowledge the chemosensitizing effect of metformin in prostate cancer has not been explored. Therefore, the hypothesis for our study was that diabetic patients with metastatic castration resistant prostate cancer who were administered metformin during docetaxel chemotherapy would have improved prostate cancer specific and overall survival.This retrospective cohort study used data from several Ontario administrative health care databases. Men older than 65 years diagnosed with metastatic castration resistant prostate cancer and treated with docetaxel were stratified into groups based on diabetes status and use of antidiabetic medications. We evaluated the effect of metformin use with docetaxel on prostate cancer specific survival and overall survival using Kaplan-Meier survival curves, the log rank test and multivariate Cox proportional HRs.Survival curves showed that metformin use with docetaxel did not improve prostate cancer specific survival (p = 0.9562) or overall survival (p = 0.9927). HRs showed no significant effect of metformin use with docetaxel on prostate cancer specific survival (HR = 0.96, p = 0.66) or overall survival (HR = 0.94, p = 0.39).Metformin use during docetaxel chemotherapy did not significantly improve prostate cancer specific or overall survival in diabetic patients with metastatic castration resistant prostate cancer. This study indicates that metformin may not be an effective chemosensitizer for metastatic castration resistant prostate cancer." @default.
• W2035994482 created "2016-06-24" @default.
• W2035994482 creator A5005231494 @default.
• W2035994482 creator A5007779528 @default.
• W2035994482 creator A5009190675 @default.
• W2035994482 creator A5048796030 @default.
• W2035994482 creator A5060580174 @default.
• W2035994482 creator A5071719212 @default.
• W2035994482 creator A5072378199 @default.
• W2035994482 creator A5072440621 @default.
• W2035994482 creator A5072850546 @default.
• W2035994482 date "2011-03-01" @default.
• W2035994482 modified "2023-10-18" @default.
• W2035994482 title "1098 ABIRATERONE ACETATE PLUS LOW-DOSE PREDNISONE HAS A FAVORABLE SAFETY PROFILE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PROGRESSING AFTER DOCETAXEL-BASED CHEMOTHERAPY: RESULTS FROM COU-AA-301, A RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED, PHASE III STUDY" @default.
• W2035994482 doi "https://doi.org/10.1016/s1569-9056(11)61076-2" @default.
• W2035994482 hasPublicationYear "2011" @default.
• W2035994482 type Work @default.
• W2035994482 sameAs 2035994482 @default.
• W2035994482 citedByCount "4" @default.
• W2035994482 countsByYear W20359944822012 @default.
• W2035994482 crossrefType "journal-article" @default.
• W2035994482 hasAuthorship W2035994482A5005231494 @default.
• W2035994482 hasAuthorship W2035994482A5007779528 @default.
• W2035994482 hasAuthorship W2035994482A5009190675 @default.
• W2035994482 hasAuthorship W2035994482A5048796030 @default.
• W2035994482 hasAuthorship W2035994482A5060580174 @default.
• W2035994482 hasAuthorship W2035994482A5071719212 @default.
• W2035994482 hasAuthorship W2035994482A5072378199 @default.
• W2035994482 hasAuthorship W2035994482A5072440621 @default.
• W2035994482 hasAuthorship W2035994482A5072850546 @default.
• W2035994482 hasConcept C121608353 @default.
• W2035994482 hasConcept C126322002 @default.
• W2035994482 hasConcept C126894567 @default.
• W2035994482 hasConcept C143998085 @default.
• W2035994482 hasConcept C2775832370 @default.
• W2035994482 hasConcept C2776694085 @default.
• W2035994482 hasConcept C2777899217 @default.
• W2035994482 hasConcept C2779306644 @default.
• W2035994482 hasConcept C2780192828 @default.
• W2035994482 hasConcept C2780323712 @default.
• W2035994482 hasConcept C2781190966 @default.
• W2035994482 hasConcept C71924100 @default.
• W2035994482 hasConceptScore W2035994482C121608353 @default.
• W2035994482 hasConceptScore W2035994482C126322002 @default.
• W2035994482 hasConceptScore W2035994482C126894567 @default.
• W2035994482 hasConceptScore W2035994482C143998085 @default.
• W2035994482 hasConceptScore W2035994482C2775832370 @default.
• W2035994482 hasConceptScore W2035994482C2776694085 @default.
• W2035994482 hasConceptScore W2035994482C2777899217 @default.
• W2035994482 hasConceptScore W2035994482C2779306644 @default.
• W2035994482 hasConceptScore W2035994482C2780192828 @default.
• W2035994482 hasConceptScore W2035994482C2780323712 @default.
• W2035994482 hasConceptScore W2035994482C2781190966 @default.
• W2035994482 hasConceptScore W2035994482C71924100 @default.
• W2035994482 hasIssue "2" @default.
• W2035994482 hasLocation W20359944821 @default.
• W2035994482 hasOpenAccess W2035994482 @default.
• W2035994482 hasPrimaryLocation W20359944821 @default.
• W2035994482 hasRelatedWork W2158933186 @default.
• W2035994482 hasRelatedWork W2568045406 @default.
• W2035994482 hasRelatedWork W2588988563 @default.
• W2035994482 hasRelatedWork W2591232777 @default.
• W2035994482 hasRelatedWork W2770702948 @default.
• W2035994482 hasRelatedWork W2804874937 @default.
• W2035994482 hasRelatedWork W2912565296 @default.
• W2035994482 hasRelatedWork W2913942481 @default.
• W2035994482 hasRelatedWork W4226040508 @default.
• W2035994482 hasRelatedWork W4229076799 @default.
• W2035994482 hasVolume "10" @default.
• W2035994482 isParatext "false" @default.
• W2035994482 isRetracted "false" @default.
• W2035994482 magId "2035994482" @default.
• W2035994482 workType "article" @default.